PARVOVIRUS B19 IN KIDNEY TRANSPLANT RECIPIENTS – A SINGLE CENTER STUDY

8 Feb 2025 12 a.m. 12 a.m.
WCN25-AB-4384, Poster Board= SAT-390

Introduction:

Parvovirus infection is a pathogenic viral infection which is the only member of the family Parvoviridae known to be pathogenic in humans.Parvovirus B19 manifestation vary with the immunologic and hematologic status of host. It is often acquired from donor during the first few months post kidney transplantation and has non-specific clinic –biological picture. The hallmark picture in immune-compromised host is red cell aplasia and chronic anemia B19 infection mainly occurs within 2 weeks after kidney transplantation.

Methods:

A retrospective analysis of  6   patients who diagnosed to have Parvo virus B 19 infection post renal transplantation in the department of Nephrology at VPS. Blood samples of kidney transplant recipient were collected and tested for Parvovirus B 19 DNA copies, IgG / IgM levels and hematological parameters and functions of kidney. 

Results:

6 patients were diagnosed with Parvo virus B 19 infection post renal transplant there were 2 males and 4 females , 3 people developed infection within 6 months of transplant and 3 people developed infection after 6 months of  kidney transplant.Patients who were infected with Parvo virus B19 after kidney transplant showed several symptoms including anemia in all 6 patients, thrombocytopenia in 1 patient, kidney function impairment in 2 patients. Of the patients infected with Parvovius B 19 infection all 6 patients had used thymoglobulin ,  maintenance immunosuppression with mycophenolate , tacrolimus and steroid. 4 patients developed graft dysfunction. No patients had graft rejection, graft loss or mortality. All 6 patients responded to IVIG.

Conclusions:

In renal transplant recipients, parvo virus B 19 infection manifested as unexplained / refractory anemia. Parvo virus B 19 infection is to be considered differential in renal transplant recipients even after 2 weeks post-transplant. Post-transplant patients have good outcome with IVIG treatment.

I have no potential conflict of interest to disclose.

I did not use generative AI and AI-assisted technologies in the writing process.